Teladoc (NYSE:TDOC) has been assigned a $39.00 target price by Craig Hallum in a report released on Wednesday, May 2nd. The brokerage currently has a “hold” rating on the health services provider’s stock. Craig Hallum’s target price points to a potential downside of 19.92% from the stock’s previous close.
Several other analysts also recently weighed in on the company. ValuEngine upgraded shares of Teladoc from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Canaccord Genuity reiterated a “buy” rating and issued a $45.00 target price on shares of Teladoc in a report on Friday, April 13th. Wells Fargo set a $46.00 price objective on shares of Teladoc and gave the company a “buy” rating in a report on Friday, April 6th. KeyCorp restated an “overweight” rating and set a $50.00 price objective (up previously from $41.00) on shares of Teladoc in a report on Thursday, March 15th. Finally, Deutsche Bank downgraded shares of Teladoc from a “buy” rating to a “hold” rating and set a $45.00 price objective on the stock. in a report on Thursday, March 15th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Teladoc currently has an average rating of “Buy” and a consensus target price of $42.67.
Teladoc opened at $48.70 on Wednesday, MarketBeat.com reports. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.15 and a quick ratio of 4.15. Teladoc has a fifty-two week low of $49.10 and a fifty-two week high of $49.75.
Teladoc (NYSE:TDOC) last issued its earnings results on Tuesday, May 1st. The health services provider reported ($0.39) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.43) by $0.04. The firm had revenue of $89.64 million during the quarter, compared to analyst estimates of $86.77 million. Teladoc had a negative net margin of 41.06% and a negative return on equity of 20.40%. The business’s revenue was up 109.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.30) earnings per share. research analysts anticipate that Teladoc will post -1.37 EPS for the current fiscal year.
In other Teladoc news, SVP Andrew Turitz sold 19,245 shares of the firm’s stock in a transaction on Friday, March 2nd. The stock was sold at an average price of $39.25, for a total value of $755,366.25. Following the completion of the sale, the senior vice president now directly owns 16,700 shares of the company’s stock, valued at approximately $655,475. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Adam C. Vandervoort sold 27,809 shares of the firm’s stock in a transaction on Friday, March 2nd. The stock was sold at an average price of $38.62, for a total value of $1,073,983.58. Following the completion of the sale, the insider now directly owns 19,338 shares of the company’s stock, valued at $746,833.56. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 483,954 shares of company stock valued at $19,960,682. Corporate insiders own 3.95% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in TDOC. SG Americas Securities LLC purchased a new position in shares of Teladoc during the 4th quarter worth $101,000. We Are One Seven LLC grew its holdings in shares of Teladoc by 241.1% during the 1st quarter. We Are One Seven LLC now owns 2,845 shares of the health services provider’s stock worth $115,000 after purchasing an additional 2,011 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Teladoc by 68.8% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,874 shares of the health services provider’s stock worth $116,000 after purchasing an additional 1,171 shares during the period. Rockefeller Capital Management L.P. purchased a new position in shares of Teladoc during the 1st quarter worth $154,000. Finally, Montag A & Associates Inc. purchased a new position in shares of Teladoc during the 4th quarter worth $200,000.
Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.